$PODD
INSULET CORP

2015 Q2 Form 10-Q Financial Statement

#000114519715000032 Filed on April 30, 2015

View on sec.gov

Income Statement

Concept 2015 Q2 2015 Q1 2014 Q1
Revenue $60.55M $48.15M $55.35M
YoY Change 5.17% -13.02% -3.49%
Cost Of Revenue $30.04M $18.96M $36.35M
YoY Change -17.14% -47.86% 12.89%
Gross Profit $30.52M $29.19M $28.43M
YoY Change -4.13% 2.67% 13.04%
Gross Profit Margin 50.4% 60.63% 51.37%
Selling, General & Admin $32.51M $28.25M $27.92M
YoY Change -5.42% 1.21% 3.52%
% of Gross Profit 106.52% 96.78% 98.17%
Research & Development $12.07M $8.207M $6.779M
YoY Change 80.75% 21.07% 54.21%
% of Gross Profit 39.55% 28.11% 23.84%
Depreciation & Amortization $3.680M $3.433M $3.070M
YoY Change 21.45% 11.82% 5.72%
% of Gross Profit 12.06% 11.76% 10.8%
Operating Expenses $44.57M $36.46M $34.69M
YoY Change 8.6% 5.09% 10.63%
Operating Profit -$14.06M -$7.266M -$1.886M
YoY Change 166.27% 285.26% -69.61%
Interest Expense -$3.200M -$3.200M $300.0K
YoY Change -1166.67% -1166.67%
% of Operating Profit
Other Income/Expense, Net -$3.193M -$3.152M -$4.193M
YoY Change -86.57% -24.83% -3.12%
Pretax Income -$17.25M -$10.42M -$6.079M
YoY Change -40.63% 71.38% -42.29%
Income Tax $15.00K $24.00K $65.00K
% Of Pretax Income
Net Earnings -$15.43M -$11.83M -$6.144M
YoY Change -46.99% 92.61% -42.39%
Net Earnings / Revenue -25.49% -24.58% -11.1%
Basic Earnings Per Share
Diluted Earnings Per Share -$271.1K -$208.8K -$110.7K
COMMON SHARES
Basic Shares Outstanding 56.75M shares 56.45M shares 55.06M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2015 Q2 2015 Q1 2014 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $145.1M $145.6M $145.6M
YoY Change -17.32% 0.0% -1.69%
Cash & Equivalents $145.1M $145.6M $146.4M
Short-Term Investments
Other Short-Term Assets $3.400M $3.700M $7.100M
YoY Change -40.35% -47.89% 10.94%
Inventory $23.44M $20.07M $10.45M
Prepaid Expenses
Receivables $31.83M $36.09M $36.68M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $203.8M $205.4M $199.9M
YoY Change -12.08% 2.79% 2.62%
LONG-TERM ASSETS
Property, Plant & Equipment $42.04M $44.61M $32.56M
YoY Change 23.07% 37.03% 30.32%
Goodwill $37.54M $37.54M $37.54M
YoY Change 0.0% 0.0% 0.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $4.687M $4.986M $1.652M
YoY Change -20.81% 201.82% -19.65%
Total Long-Term Assets $96.56M $100.3M $88.67M
YoY Change 3.28% 13.1% 2.94%
TOTAL ASSETS
Total Short-Term Assets $203.8M $205.4M $199.9M
Total Long-Term Assets $96.56M $100.3M $88.67M
Total Assets $300.4M $305.7M $288.5M
YoY Change -7.66% 5.96% 2.72%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $17.92M $14.25M $20.98M
YoY Change -3.73% -32.11% 145.59%
Accrued Expenses $26.44M $25.27M $18.77M
YoY Change 7.54% 34.61% 4.16%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $6.200M $6.000M $2.800M
YoY Change -74.03% 114.29% -81.0%
Total Short-Term Liabilities $52.68M $47.38M $43.12M
YoY Change -26.01% 9.88% 0.32%
LONG-TERM LIABILITIES
Long-Term Debt $172.2M $170.6M $116.3M
YoY Change 3.83% 46.71% 9.5%
Other Long-Term Liabilities $2.921M $3.038M $1.984M
YoY Change 92.04% 53.13% -9.24%
Total Long-Term Liabilities $175.1M $173.6M $118.3M
YoY Change 4.63% 46.82% 9.13%
TOTAL LIABILITIES
Total Short-Term Liabilities $52.68M $47.38M $43.12M
Total Long-Term Liabilities $175.1M $173.6M $118.3M
Total Liabilities $230.1M $225.0M $166.0M
YoY Change -5.09% 35.5% 9.7%
SHAREHOLDERS EQUITY
Retained Earnings -$605.3M -$589.9M -$532.7M
YoY Change 7.75% 10.74% 8.22%
Common Stock $57.00K $57.00K $55.00K
YoY Change 3.64% 3.64% 3.77%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $70.26M $80.74M $122.5M
YoY Change
Total Liabilities & Shareholders Equity $300.4M $305.7M $288.5M
YoY Change -7.66% 5.96% 2.72%

Cashflow Statement

Concept 2015 Q2 2015 Q1 2014 Q1
OPERATING ACTIVITIES
Net Income -$15.43M -$11.83M -$6.144M
YoY Change -46.99% 92.61% -42.39%
Depreciation, Depletion And Amortization $3.680M $3.433M $3.070M
YoY Change 21.45% 11.82% 5.72%
Cash From Operating Activities $790.0K -$3.488M -$1.017M
YoY Change 54.9% 242.97% -15.25%
INVESTING ACTIVITIES
Capital Expenditures -$250.0K $4.346M $2.157M
YoY Change -93.04% 101.48% 101.78%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$250.0K -$4.346M -$2.157M
YoY Change -93.04% 101.48% 101.78%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $4.876M $3.561M
YoY Change 36.93% -96.23%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -1.000M $2.249M -$939.0K
YoY Change -103.03% -339.51% -101.01%
NET CHANGE
Cash From Operating Activities 790.0K -$3.488M -$1.017M
Cash From Investing Activities -250.0K -$4.346M -$2.157M
Cash From Financing Activities -1.000M $2.249M -$939.0K
Net Change In Cash -460.0K -$5.585M -$4.113M
YoY Change -101.54% 35.79% -104.53%
FREE CASH FLOW
Cash From Operating Activities $790.0K -$3.488M -$1.017M
Capital Expenditures -$250.0K $4.346M $2.157M
Free Cash Flow $1.040M -$7.834M -$3.174M
YoY Change -74.63% 146.82% 39.89%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2015Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2015Q1 dei Amendment Flag
AmendmentFlag
false
CY2015Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2015Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2015
CY2015Q1 dei Document Period End Date
DocumentPeriodEndDate
2015-03-31
CY2015Q1 dei Document Type
DocumentType
10-Q
CY2015Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001145197
CY2015Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
56750931 shares
CY2015Q1 dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
CY2015Q1 dei Entity Registrant Name
EntityRegistrantName
INSULET CORP
CY2015Q1 dei Trading Symbol
TradingSymbol
PODD
CY2014Q1 podd Debt Instrument Stated Coupon Rate Interest Expense
DebtInstrumentStatedCouponRateInterestExpense
1348000 USD
CY2015Q1 podd Debt Instrument Stated Coupon Rate Interest Expense
DebtInstrumentStatedCouponRateInterestExpense
1006000 USD
CY2014Q1 podd Increase Decrease In Accounts Payable Accrued Expenses And Other Liabilities
IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities
917000 USD
CY2015Q1 podd Increase Decrease In Accounts Payable Accrued Expenses And Other Liabilities
IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities
-59000 USD
CY2014Q1 podd Interestand Other Expense Total
InterestandOtherExpenseTotal
4119000 USD
CY2015Q1 podd Interestand Other Expense Total
InterestandOtherExpenseTotal
2889000 USD
CY2014Q4 podd Number Of Customers With Greater Than Ten Percent Accounts Receivable Balance
NumberOfCustomersWithGreaterThanTenPercentAccountsReceivableBalance
2 customer
CY2014Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
14659000 USD
CY2015Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
14246000 USD
CY2014Q4 us-gaap Accounts Receivable Gross Current
AccountsReceivableGrossCurrent
45719000 USD
CY2015Q1 us-gaap Accounts Receivable Gross Current
AccountsReceivableGrossCurrent
41469000 USD
CY2014Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
39882000 USD
CY2015Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
36093000 USD
CY2014Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
24703000 USD
CY2015Q1 podd Number Of Customers With Greater Than Ten Percent Accounts Receivable Balance
NumberOfCustomersWithGreaterThanTenPercentAccountsReceivableBalance
1 customer
CY2015Q1 podd Number Of Financial Institution
NumberOfFinancialInstitution
2 location
CY2015Q1 podd Number Of Inches Of Tubing In Conventional Insulin Pump
NumberOfInchesOfTubingInConventionalInsulinPump
42 in
CY2014Q1 podd Number Of Single Source Suppliers
NumberOfSingleSourceSuppliers
1 customer
CY2015Q1 podd Number Of Single Source Suppliers
NumberOfSingleSourceSuppliers
1 customer
CY2014 podd Percentage Of Accounts Payable Accrued Expensesand Other Current Liabilities
PercentageOfAccountsPayableAccruedExpensesandOtherCurrentLiabilities
0.24
CY2015Q1 podd Percentage Of Accounts Payable Accrued Expensesand Other Current Liabilities
PercentageOfAccountsPayableAccruedExpensesandOtherCurrentLiabilities
0.23
CY2015Q1 podd Percentof Revenue
PercentofRevenue
0.10
CY2015Q1 podd Product Warranty Term
ProductWarrantyTerm
P4Y
CY2015Q1 podd Return Period
ReturnPeriod
P45D
CY2015Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
25267000 USD
CY2015Q1 us-gaap Acquired Finite Lived Intangible Assets Weighted Average Useful Life
AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
P7Y
CY2014Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
661798000 USD
CY2015Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
670544000 USD
CY2014Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4400000 USD
CY2015Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5300000 USD
CY2014Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
5837000 USD
CY2015Q1 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
5376000 USD
CY2014Q1 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
2625000 USD
CY2015Q1 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
1601000 USD
CY2014Q1 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
146000 USD
CY2015Q1 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
282000 USD
CY2014Q1 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
2528000 USD
CY2015Q1 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
1883000 USD
CY2014Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1100000 USD
CY2015Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
900000 USD
CY2014Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8234419 shares
CY2015Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8058463 shares
CY2014Q4 us-gaap Assets
Assets
302156000 USD
CY2015Q1 us-gaap Assets
Assets
305716000 USD
CY2014Q4 us-gaap Assets Current
AssetsCurrent
208196000 USD
CY2015Q1 us-gaap Assets Current
AssetsCurrent
205427000 USD
CY2014Q4 us-gaap Capital Lease Obligations Current
CapitalLeaseObligationsCurrent
3380000 USD
CY2015Q1 us-gaap Capital Lease Obligations Current
CapitalLeaseObligationsCurrent
5996000 USD
CY2014Q1 us-gaap Capital Lease Obligations Incurred
CapitalLeaseObligationsIncurred
0 USD
CY2015Q1 us-gaap Capital Lease Obligations Incurred
CapitalLeaseObligationsIncurred
5721000 USD
CY2014Q4 us-gaap Capital Lease Obligations Noncurrent
CapitalLeaseObligationsNoncurrent
2263000 USD
CY2015Q1 us-gaap Capital Lease Obligations Noncurrent
CapitalLeaseObligationsNoncurrent
3965000 USD
CY2015Q1 us-gaap Capital Leases Future Minimum Payments Due
CapitalLeasesFutureMinimumPaymentsDue
11193000 USD
CY2015Q1 us-gaap Capital Leases Future Minimum Payments Due Current
CapitalLeasesFutureMinimumPaymentsDueCurrent
5639000 USD
CY2014Q1 us-gaap Capital Leases Income Statement Interest Expense
CapitalLeasesIncomeStatementInterestExpense
300000 USD
CY2015Q1 us-gaap Capital Leases Future Minimum Payments Due In Two Years
CapitalLeasesFutureMinimumPaymentsDueInTwoYears
269000 USD
CY2015Q1 us-gaap Capital Leases Future Minimum Payments Interest Included In Payments
CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments
1232000 USD
CY2015Q1 us-gaap Capital Leases Future Minimum Payments Present Value Of Net Minimum Payments
CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments
9961000 USD
CY2015Q1 us-gaap Capital Leases Future Minimum Payments Remainder Of Fiscal Year
CapitalLeasesFutureMinimumPaymentsRemainderOfFiscalYear
5285000 USD
CY2015Q1 us-gaap Capital Leases Income Statement Interest Expense
CapitalLeasesIncomeStatementInterestExpense
300000 USD
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
149727000 USD
CY2014Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
145614000 USD
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
151193000 USD
CY2015Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
145608000 USD
CY2014Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
123141000 USD
CY2015Q1 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
123155000 USD
CY2014Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-4113000 USD
CY2015Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-5585000 USD
CY2014Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2015Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2014Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2015Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2014Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2015Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2014Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
56299022 shares
CY2015Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
56704347 shares
CY2014Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
56299022 shares
CY2015Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
56704347 shares
CY2014Q4 us-gaap Common Stock Value
CommonStockValue
56000 USD
CY2015Q1 us-gaap Common Stock Value
CommonStockValue
57000 USD
CY2014Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
36353000 USD
CY2015Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
28408000 USD
CY2014Q1 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
31000 USD
CY2015Q1 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
24000 USD
CY2014Q3 us-gaap Debt Conversion Converted Instrument Shares Issued1
DebtConversionConvertedInstrumentSharesIssued1
348535 shares
CY2014Q4 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
32256000 USD
CY2015Q1 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
30655000 USD
CY2014Q4 us-gaap Deferred Finance Costs Noncurrent Net
DeferredFinanceCostsNoncurrentNet
4974000 USD
CY2015Q1 us-gaap Deferred Finance Costs Noncurrent Net
DeferredFinanceCostsNoncurrentNet
4693000 USD
CY2014Q1 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
34000 USD
CY2015Q1 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
28000 USD
CY2014Q4 us-gaap Deferred Revenue
DeferredRevenue
1600000 USD
CY2015Q1 us-gaap Deferred Revenue
DeferredRevenue
1900000 USD
CY2014Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
1554000 USD
CY2015Q1 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
1867000 USD
CY2014Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
3070000 USD
CY2015Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
3433000 USD
CY2014Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.11
CY2015Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.21
CY2015Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
50200000 USD
CY2014Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
18836000 USD
CY2015Q1 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
19745000 USD
CY2015Q1 us-gaap Finite Lived Intangible Assets Amortization Expense After Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive
2656000 USD
CY2015Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
2665000 USD
CY2015Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year
FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
2342000 USD
CY2015Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
1496000 USD
CY2015Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
1806000 USD
CY2015Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
2190000 USD
CY2014Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
32900000 USD
CY2015Q1 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
32900000 USD
CY2014Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
14064000 USD
CY2015Q1 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
13155000 USD
CY2011 us-gaap Finitelived Intangible Assets Acquired1
FinitelivedIntangibleAssetsAcquired1
32900000 USD
CY2014 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
23200000 USD
CY2014Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
14259000 USD
CY2015Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
15829000 USD
CY2014Q4 us-gaap Goodwill
Goodwill
37536000 USD
CY2015Q1 us-gaap Goodwill
Goodwill
37536000 USD
CY2014Q1 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0 USD
CY2015Q1 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0 USD
CY2014Q1 us-gaap Gross Profit
GrossProfit
32808000 USD
CY2015Q1 us-gaap Gross Profit
GrossProfit
32807000 USD
CY2014Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-6079000 USD
CY2015Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-11782000 USD
CY2014Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
65000 USD
CY2015Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
52000 USD
CY2014Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
4503000 USD
CY2015Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-3461000 USD
CY2014Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-288000 USD
CY2015Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
313000 USD
CY2014Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
985000 USD
CY2015Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
6966000 USD
CY2014Q1 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
41000 USD
CY2015Q1 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
264000 USD
CY2014Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
904000 USD
CY2015Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-384000 USD
CY2014Q1 us-gaap Interest Expense Debt
InterestExpenseDebt
4489000 USD
CY2015Q1 us-gaap Interest Expense Debt
InterestExpenseDebt
3193000 USD
CY2014Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
11992000 USD
CY2015Q1 us-gaap Inventory Finished Goods
InventoryFinishedGoods
18449000 USD
CY2014Q4 us-gaap Inventory Net
InventoryNet
13099000 USD
CY2015Q1 us-gaap Inventory Net
InventoryNet
20065000 USD
CY2014Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
853000 USD
CY2015Q1 us-gaap Inventory Raw Materials
InventoryRawMaterials
1616000 USD
CY2014Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
254000 USD
CY2015Q1 us-gaap Inventory Work In Process
InventoryWorkInProcess
0 USD
CY2014Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
31000 USD
CY2015Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
36000 USD
CY2014Q4 us-gaap Liabilities
Liabilities
218327000 USD
CY2015Q1 us-gaap Liabilities
Liabilities
224974000 USD
CY2014Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
302156000 USD
CY2015Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
305716000 USD
CY2014Q4 us-gaap Liabilities Current
LiabilitiesCurrent
44296000 USD
CY2015Q1 us-gaap Liabilities Current
LiabilitiesCurrent
47376000 USD
CY2014Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
168994000 USD
CY2015Q1 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
170595000 USD
CY2014Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-939000 USD
CY2015Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2249000 USD
CY2014Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-2157000 USD
CY2015Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-4346000 USD
CY2014Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1017000 USD
CY2015Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3488000 USD
CY2014Q1 us-gaap Net Income Loss
NetIncomeLoss
-6144000 USD
CY2015Q1 us-gaap Net Income Loss
NetIncomeLoss
-11834000 USD
CY2014Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-4193000 USD
CY2015Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-3152000 USD
CY2015Q1 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 segment
CY2014Q1 us-gaap Operating Expenses
OperatingExpenses
34694000 USD
CY2015Q1 us-gaap Operating Expenses
OperatingExpenses
41437000 USD
CY2014Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-1886000 USD
CY2015Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-8630000 USD
CY2015Q1 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
16691000 USD
CY2015Q1 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
2196000 USD
CY2015Q1 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
2181000 USD
CY2015Q1 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
2290000 USD
CY2015Q1 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
2284000 USD
CY2015Q1 us-gaap Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
6080000 USD
CY2015Q1 us-gaap Operating Leases Future Minimum Payments Remainder Of Fiscal Year
OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear
1660000 USD
CY2013Q4 us-gaap Other Assets Fair Value Disclosure
OtherAssetsFairValueDisclosure
200000 USD
CY2014Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
5291000 USD
CY2015Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
4986000 USD
CY2014Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
2774000 USD
CY2015Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
3038000 USD
CY2014Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
265000 USD
CY2015Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
5000 USD
CY2014Q1 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
3882000 USD
CY2015Q1 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
1434000 USD
CY2014Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2157000 USD
CY2015Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
4346000 USD
CY2014Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2015Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2014Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2015Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2014Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2015Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2014Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2015Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2014Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2015Q1 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2014Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4022000 USD
CY2015Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3661000 USD
CY2014Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
3561000 USD
CY2015Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
4876000 USD
CY2013Q4 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
3090000 USD
CY2014Q1 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
3100000 USD
CY2014Q4 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
2614000 USD
CY2015Q1 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
2661000 USD
CY2014Q4 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
981000 USD
CY2015Q1 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
975000 USD
CY2014Q4 us-gaap Product Warranty Accrual Noncurrent
ProductWarrantyAccrualNoncurrent
1633000 USD
CY2015Q1 us-gaap Product Warranty Accrual Noncurrent
ProductWarrantyAccrualNoncurrent
1686000 USD
CY2014Q1 us-gaap Product Warranty Accrual Payments
ProductWarrantyAccrualPayments
683000 USD
CY2015Q1 us-gaap Product Warranty Accrual Payments
ProductWarrantyAccrualPayments
420000 USD
CY2014Q1 us-gaap Product Warranty Accrual Warranties Issued
ProductWarrantyAccrualWarrantiesIssued
693000 USD
CY2015Q1 us-gaap Product Warranty Accrual Warranties Issued
ProductWarrantyAccrualWarrantiesIssued
467000 USD
CY2014Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
37069000 USD
CY2015Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
44612000 USD
CY2014Q1 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
891000 USD
CY2015Q1 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
328000 USD
CY2014Q1 us-gaap Repayments Of Long Term Capital Lease Obligations
RepaymentsOfLongTermCapitalLeaseObligations
618000 USD
CY2015Q1 us-gaap Repayments Of Long Term Capital Lease Obligations
RepaymentsOfLongTermCapitalLeaseObligations
1193000 USD
CY2014Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6779000 USD
CY2015Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8207000 USD
CY2014Q4 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
1200000 USD
CY2015Q1 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
1200000 USD
CY2014Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-578025000 USD
CY2015Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-589859000 USD
CY2014Q1 us-gaap Sales Revenue Net
SalesRevenueNet
69161000 USD
CY2015Q1 us-gaap Sales Revenue Net
SalesRevenueNet
61215000 USD
CY2014Q1 us-gaap Segment Reporting Disclosure Of Major Customers
SegmentReportingDisclosureOfMajorCustomers
2
CY2015Q1 us-gaap Segment Reporting Disclosure Of Major Customers
SegmentReportingDisclosureOfMajorCustomers
0
CY2014Q1 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
13656000 USD
CY2015Q1 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
17401000 USD
CY2014Q1 us-gaap Share Based Compensation
ShareBasedCompensation
4360000 USD
CY2015Q1 us-gaap Share Based Compensation
ShareBasedCompensation
5305000 USD
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
999090 shares
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
830911 shares
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
25.27
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
6958000 USD
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
30722 shares
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
1271391 shares
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
12063000 USD
CY2015Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
8401000 USD
CY2015Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y7M17D
CY2015Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y6M0D
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1847669 shares
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2769259 shares
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
26.99
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
31.53
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
11696000 USD
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
2538150 shares
CY2015Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
15.35
CY2015Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
28.11
CY2015Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
33.98
CY2015Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
319079 shares
CY2014Q3 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
12600000 USD
CY2014Q4 us-gaap Stockholders Equity
StockholdersEquity
83829000 USD
CY2015Q1 us-gaap Stockholders Equity
StockholdersEquity
80742000 USD
CY2015Q1 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0 USD
CY2014Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
55089028 shares
CY2015Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
56496648 shares
CY2015Q1 us-gaap Nature Of Operations
NatureOfOperations
<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Nature of the Business</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company is primarily engaged in the development, manufacturing and sale of its proprietary OmniPod Insulin Management System (the &#8220;OmniPod System&#8221;), an innovative, discreet and easy-to-use insulin infusion system for people with insulin-dependent diabetes. The OmniPod System features a unique disposable tubeless OmniPod which is worn on the body for approximately three days at a time and the handheld, wireless Personal Diabetes Manager (&#8220;PDM&#8221;). Conventional insulin pumps require people with insulin-dependent diabetes to learn to use, manage and wear a number of cumbersome components, including up to </font><font style="font-family:Arial;font-size:10pt;color:#000000;text-decoration:none;">42</font><font style="font-family:Arial;font-size:10pt;"> inches of tubing. In contrast, the OmniPod System features two discreet, easy-to-use devices that eliminate the need for a bulky pump, tubing and separate blood glucose meter, provides for virtually pain-free automated cannula insertion, communicates wirelessly and integrates a blood glucose meter. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In </font><font style="font-family:Arial;font-size:10pt;">June 2011</font><font style="font-family:Arial;font-size:10pt;">, the Company acquired Neighborhood Holdings, Inc. and its wholly-owned subsidiaries (collectively, &#8220;Neighborhood Diabetes&#8221;) in order to expand the Company&#8217;s full-suite diabetes management product offerings and obtain access to a larger number of insulin dependent patients. Through Neighborhood Diabetes, the Company is able to provide customers with blood glucose testing supplies, traditional insulin pumps, pump supplies and pharmaceuticals and has the ability to process claims as either durable medical equipment or through pharmacy benefits.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company began commercial sale of the OmniPod System in the United States in </font><font style="font-family:Arial;font-size:10pt;">2005</font><font style="font-family:Arial;font-size:10pt;">. The Company sells the OmniPod System and other diabetes management supplies in the United States through direct sales to customers or through its distribution partners. The OmniPod System is currently available in multiple countries in Europe and in Canada. The Company has been selling its new OmniPod System since 2013. The new OmniPod System is approximately one-third smaller and one-quarter lighter than the original model, while maintaining the same features and operating capabilities.</font></div></div>
CY2015Q1 us-gaap Use Of Estimates
UseOfEstimates
<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Use of Estimates in Preparation of Financial Statements</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenue and expense during the reporting periods. The most significant estimates used in these financial statements include the valuation of stock-based compensation expense, accounts receivable, inventories, goodwill, deferred revenue, and equity instruments, the lives of property and equipment and intangible assets, as well as warranty and doubtful accounts allowance reserve calculations. Actual results may differ from those estimates.</font></div></div>

Files In Submission

Name View Source Status
0001145197-15-000032-index-headers.html Edgar Link pending
0001145197-15-000032-index.html Edgar Link pending
0001145197-15-000032.txt Edgar Link pending
0001145197-15-000032-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
Financial_Report.xlsx Edgar Link pending
podd-20150331.xml Edgar Link completed
podd-20150331.xsd Edgar Link pending
podd-20150331_cal.xml Edgar Link unprocessable
podd-20150331_def.xml Edgar Link unprocessable
podd-20150331_lab.xml Edgar Link unprocessable
podd-20150331_pre.xml Edgar Link unprocessable
podd-2015x03x31_10xq.htm Edgar Link pending
podd-ex311_20150331x10q.htm Edgar Link pending
podd-ex312_20150331x10q.htm Edgar Link pending
podd-ex321_20150331x10q.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending